Onconephrology Symposium
- Continuing Education
Advance your onconephrology expertise by joining a dynamic, expert-led symposium designed to equip clinicians with up-to-date knowledge at the intersection of cancer and kidney care. Gain practical insights, emerging evidence, and multidisciplinary strategies to better diagnose, manage, and support the growing population of cancer patients facing complex renal conditions.
- Live Online or In Person
This course is taught in person and live online.
Dana Farber Cancer Institute | 450 Brookline Avenue, Boston, MA 02215
$500
For a full list of profession pricing see below.
View All
Continuing Education
Earn up to:
15.25 AMA PRA Category 1 Credit(s) ™
View All
Two Days
Please view the Schedule for a full description of the program.
On This Page
Overview
At least 1 out of every 10 cancer patients will experience acute kidney injury, and up to 25% will have chronic kidney disease. Cancer is a common global problem, and as cancer treatments evolve, nephrologists will be tasked with diagnosing and managing more complex cases within this cohort of patients. The 2026 Onconephrology Symposium will offer up to date information and insights from national and international experts in this constantly evolving subspecialty. The goal of this forum is to provide an opportunity for academicians and clinicians to have personal exchanges with experts in this steadily expanding subspecialty in order to enhance the clinical experience of our cancer patients. Topics covered will include an update on cancer therapies and renal impact, paraneoplastic glomerular disorders, thrombotic microangiopathy, and monoclonal disorders, to name a few. This symposium is intended for physicians, advanced practice providers, nurses, medical students, and other health care professionals in Hospital Medicine, Internal Medicine, Nephrology, Hematology, and Oncology.
Learning Objectives
- Diagnose and manage various forms of renal complications in patients with cancer.
- Learn to work in a multi-disciplinary group of providers to enhance the experience of our patients with cancer.
- Review cancer associated with glomerular disease, thrombotic microangiopathy, and monoclonal gammopathies with updates on latest diagnostics and management.
- Consider the role of kidney transplant in patients with cancer.
- Understand the landscape of cancer therapy including chemo, cellular, immune, and targeted therapy with update on reno-protective strategies.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Brigham and Women's Hospital and Dana-Farber Cancer Institute.
Schedule
All agenda sessions are in Eastern Time.
Thursday, September 17, 2026
Registration/ Breakfast
7:00-7:30 am
Welcome From Course Directors
7:30-7:45 am
What Do BMT Docs Wish Nephrologists Knew about HSCT?
7:45-8:10 am
Changing Diagnostic and Treatment Landscape of HSCT-TMA
8:10-8:35 am
Cancer and Complementology
8:35-9:00 am
Murine Models and Immune Therapy: What Can Mice Teach us About AIN?
9:00-9:25 am
Break
9:25-9:40 am
Beyond Biopsy: Biomarkers and Treatments for ICI-AKI
9:40-10:05 am
Lessons from Non-Renal Immune Related Adverse Events
10:05-10:30 am
ICI-GN: A Conundrum
10:30-11:10 am
Lunch Break/ Poster Review
11:10 am-12:10 pm
Toxicities of CAR-T and CAR-Treg
12:10-12:30 pm
How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment
12:30-12:50 pm
Q&A
12:50-1:00 pm
MAGnificent properties of Cisplatin: mitigating risk and managing AKI
1:00-1:25 pm
Target Trial Emulation in Onconephrology
1:25-1:50 pm
What’s the GFR!? Current Challenges in Cancer and Future Opportunities
1:50-2:15 pm
How Would I Dose Chemotherapy? A Case Review
2:15-2:40 pm
Break
2:40-2:50 pm
Podocytes: An Innocent Bystander in Cancer
2:50-3:15 pm
Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors ?
3:15-3:40 pm
SGLT2is: Are they a Miracle For Cancer- Associated Nephrotoxicity Too?
3:40-4:05 pm
Immune Complex Disease in Cancer: Future of Antigens
4:05-4:30 pm
Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge?
4:30-5:10 pm
Palliative Care in Onconephrology: Symptom Management and Decision Support
5:10-5:35 pm
Adjourn
5:35-5:45 pm
Friday, September 18, 2026
Registration/Breakfast
7:00-7:30 am
The Other Renal Amyloids: It’s not ALL about AL Amyloid
7:30-7:55 am
Pathophysiology of Cancer Therapy and Cardiotoxicity
7:55-8:20 am
MGUS to Myeloma: Bench to the Bedside
8:20-8:45 am
IKMG Update on MGRS: Future Associations and Mechanisms
8:45-9:05 am
How do Immunoglobulins Cause Kidney Damage?
9:05-9:25 am
Q&A
9:25-9:35 am
Break
9:35-9:45 am
The Onconephrology VS Artificial Intelligence Challenge
9:45-10:10 am
How I Manage IgM Disease and Systemic Impact
10:10-10:35 am
Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific)
10:35-11:00 am
Kidney Transplant Outcomes in Monoclonal Disorders
11:00-11:25 am
Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist
11:25-11:50 am
Clone Wars Case Debate Case: PLEX or NO Plex
11:50 am-12:30 pm
Final Reflections/Poster Winners
12:30-12:40 pm
The content of this course meets the standards of the ASON:
Faculty
Harvard Medical School Continuing Education attracts the best and brightest faculty from all around the world. As a student in this course, you’ll have access to outstanding course directors and faculty.
Course Directors
Raad Chowdhury
MD, FASN | Course Director
- Medical Director of Onconephrology Brigham and Women's/Dana Farber Cancer Institute
- APD of Mass General Brigham Nephrology Fellowship, Harvard Medical School
Shruti Gupta
MD, MPH | Course Director
- Director of Onconephrology, Brigham and Women's/Dana Farber Cancer Institute
- Assistant Professor, Harvard Medical School
Ala Abudayyeh, MD
Associate Professor and Director of Clinical Research, MD Anderson Cancer Center
Allison Betof, MD, PhD
Director, Solid Tumor Cellular Therapy;
Associate Professor, Stanford University School of Medicine
Christopher Blosser, MD
Director, Center for Innovations in Cancer & Transplant (CICT), and Cancer & Organ Transplant Clinic (COTC)
Professor of Medicine, University of Washington and Fred Hutch Cancer Center
Jorge J. Castillo, MD
Clinical Director, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute
Associate Professor, Harvard Medical School
Api Chewcharat, MD
Instructor in Medicine, Brigham and Women's Hospital, Harvard Medical School
Corey Cutler, MD, MPH
Past President, American Society for Transplantation and Cellular Therapy;
Director, Adult Stem Cell Transplantation Program, Dana Farber Cancer Institute
Samantha Gelfand, MD
Assistant Professor, Co-Director of KidneyPal Outpatient Clinic
Associate Program Director, Harvard Interprofessional Palliative Care Fellowship Harvard Medical School
Sandra M. Herrmann, MD
Professor of Medicine, Mayo Clinic
Abdullah Jalal, MD
Brigham and Women's Hospital;
Instructor in Medicine, Harvard Medical School
Anuja Java, MD
Associate Professor, Washington University
Kenar Jhaveri, MD
Professor of Medicine, Associate Chief in the Division of Kidney Diseases and Hypertension, Northwell Health and Zucker School of Medicine
Abhijat Kitchlu, MD, MSc, FRCPC
Director, University Health Network Onco-Nephrology Program;
Assistant Professor, University of Toronto
David E. Leaf, MD
Associate Professor, Brigham and Women's Hospital, Harvard Medical School
Nelson Leung, MD
Professor of Medicine, David L. and Colleen B. Kessenich Professor in Multiple Myeloma, Mayo Clinic
Sujal Shah, MD
Program Director, Brigham and Women's Hospital Medical Renal Pathology Fellowship Program
Nikhil C. Munshi, MD
Immediate Past President, International Myeloma Society;
Director, Basic and Correlative Science Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute;
Professor of Medicine, Harvard Medical School
Samih H. Nasr, MD
Professor of Labratory Medicine and Pathology, Mayo Clinic
Sarah Nikiforow, MD, PhD
Technical Director, Immune Effector Cell Therapy Program;
Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility, Dana Farber Cancer Institute;
Assistant Professor of Medicine, Harvard Medical School
Vaishali Sanchorawala, MD
Director, Amyloidosis Center;
Director, Stem Cell Transplant, Boston Medical Center;
Professor, Boston University
Harish Seethapathy, MD
Assistant Professor, Massachusetts General Hospital, Harvard Medical School
Aisha Shaikh, MD, PhD
Director, Onconephrology, University of Pennsylvania
Elad Sharon, MD, MPH
Clinical and Translational Director of the Immunotherapy Toxicity Program, Dana-Farber Cancer Institute;
Associate Professor of Medicine, Harvard Medical School
Christophe Sirac, PhD
Professor of Immunology, University of Limoges
Meghan Sise, MD
Director, Onconephrology, Massachusetts General Hospital (MGH);
Associate Professor of Medicine, Harvard Medical School.
María José Soler, MD, PhD
Chief, Clinical Nephrology and Dialysis Unit, Hospital Universitari Vall d'Hebron
Sumithra Vasu, MD
Professor of Medicine, Ohio State University
Astrid Weins, MD, PhD
Chief, Renal Pathology, Mass General Brigham;
Assistant Professor, Harvard Medical School
Biruh T. Workeneh, MD, FASN
Associate Professor, MD Anderson Cancer Center
Request Information
Interested in learning more about this program? Sign up for details.
Course Fees
Registration Details
You may register through our secure online environment and will receive an email confirmation upon receipt of your payment. Prices include CME credit, electronic syllabus. At the end of the registration process, a $10 non-refundable processing fee will be added to your registration.
| Role | Course Fee |
|---|---|
| Physician (MD/DO) | $500 |
| PA | $400 |
| Resident/Fellow | $250 |
| Allied Health Professional / Other | $750 |